Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2023-12-27 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
国浩律师（深圳）事务所关于公司2023年第二次临时股东大会之法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, procedures, qualifications of attendees, agenda, and voting results of the company's 2023 second extraordinary general meeting of shareholders. It includes detailed legal compliance checks and validation of the meeting process and resolutions. The content focuses on the legal opinion about the shareholder meeting and its resolutions, not the meeting materials themselves or the voting results announcement alone. This matches the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it provides official results and legal validation of the shareholder vote outcomes. The document length is about 4884 characters, which is sufficient to contain substantive content rather than a brief announcement. Therefore, the best classification is DVA with high confidence.
2023-12-27 Chinese
关于预计触发转股价格向下修正条件的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from a company regarding the potential triggering of a downward adjustment condition for the conversion price of its convertible bonds. It details the bond issuance, listing, conversion price adjustments, and the conditions and procedures for further downward adjustment of the conversion price. The document is an informative notice about a specific event related to the company's convertible bonds and does not contain financial statements, audit information, or detailed financial results. It is not a full financial report but rather a regulatory announcement about bond terms and potential price adjustments. The document length is 3320 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, it fits best under the category of Capital/Financing Update (CAP), as it relates to convertible bond terms and potential changes in capital structure through conversion price adjustments.
2023-12-20 Chinese
关于修订《公司章程》及相关治理制度的公告
Governance Information Classification · 95% confidence The document is an announcement regarding the revision of the company's Articles of Association and related governance systems. It details the reasons for the revisions, specific changes made to the Articles of Association, and related governance rules. It references the approval by the board of directors and mentions that the revised documents will be submitted to the shareholders' meeting for approval. The document is a formal announcement of governance changes and does not contain financial statements or detailed financial data. It is not a full annual report, interim report, or earnings release. It is not a proxy solicitation or voting results announcement. The content fits best under Governance Information (CGR) as it details the company's internal rules, board structure, and governance practices.
2023-12-11 Chinese
董事会战略委员会议事规则（2023年12月）
Governance Information Classification · 95% confidence The document is titled '健帆生物科技集团股份有限公司 董事会战略委员会议事规则' which translates to 'Rules of Procedure for the Board Strategy Committee of Jianfan Biotechnology Group Co., Ltd.' It details the composition, responsibilities, meeting procedures, and operational rules of the Board Strategy Committee. There is no financial data, no mention of fiscal periods, no audit or financial results, and no regulatory filings or announcements. The content is focused on governance structure and internal board committee rules. Therefore, it fits best under Governance Information (CGR). The document length is 2942 characters, which is consistent with a detailed governance document rather than a brief announcement or report publication notice.
2023-12-11 Chinese
董事会提名委员会议事规则（2023年12月）
Governance Information Classification · 95% confidence The document is titled '董事会提名委员会议事规则' which translates to 'Board Nomination Committee Meeting Rules'. It details the composition, responsibilities, meeting procedures, and governance rules of the nomination committee under the board of directors. There is no financial data, no mention of financial results, no voting results, no announcements of reports, or any other regulatory filings. The content is focused on governance structure and internal rules related to board nominations and committee operations. This fits the definition of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is under 5,000 characters but it is a full governance rules document, not a mere announcement. Therefore, the appropriate classification is CGR with high confidence.
2023-12-11 Chinese
委托理财管理制度（2023年12月）
Governance Information Classification · 95% confidence The document is titled '健帆生物科技集团股份有限公司 委托理财管理制度' which translates to 'JH Biotech Group Co., Ltd. Entrusted Financial Management System'. It is a detailed internal policy document outlining the principles, approval processes, risk control, accounting, and disclosure requirements related to the company's entrusted financial management activities. It references relevant laws, regulations, and company governance rules. The document is not a financial report, earnings release, or announcement of voting results. It is a governance-related internal control and management policy document. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length (5025 characters) and content confirm it is a full policy document, not a brief announcement or certification.
2023-12-11 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.